Navigation Links
ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03),Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival,Advantage for Patients with Multiple Myeloma

ut REVLIMID(R) (lenalidomide) and the RevAssist(R) program on the Internet at www.REVLIMID.com or by calling the manufacturer's toll-free number at 1-888-423-5436.

ADDITIONAL WARNINGS: HEMATOLOGIC TOXICITY

Multiple Myeloma

In the pooled multiple myeloma studies Grade 3 and 4 hematologic toxicities were more frequent in patients treated with the combination of REVLIMID(R) (lenalidomide) and dexamethasone than in patients treated with dexamethasone alone. Patients on therapy should have their complete blood counts monitored every 2 weeks for the first 12 weeks and then monthly thereafter. Patients may require dose interruption and/or dose reduction.

CONTRAINDICATIONS:

Hypersensitivity: REVLIMID(R) (lenalidomide) is contraindicated in any patients who have demonstrated hypersensitivity to the drug or its components.

PRECAUTIONS:

Renal impairment: REVLIMID(R) (lenalidomide) is substantially excreted by the kidney, so the risk of toxic reactions may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it would be prudent to monitor renal function.

Nursing mothers: It is not known whether REVLIMID(R) (lenalidomide) is excreted in human milk. Because of the potential for adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or the drug, taking into account the importance of the drug to the mother.

ADVERSE REACTIONS:

Multiple Myeloma:

In the REVLIMID(R) (lenalidomide)/dexamethasone treatment group, 151 patients (45%) underwent at least one dose interruption with or without a dose reduction of REVLIMID(R) (lenalidomide) compared to 21% in the placebo/dexamethasone treatment group. Of these patients who had one dose interruption with or without a dose reduction, 50% in the REVLIMID(R) (le
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:5/28/2015)... , May 28, 2015 Zimmer Holdings, ... it has finalized agreements with buyers to divest in ... Unicompartmental High-Flex Knee System assets, Biomet Discovery® Elbow System ... are in furtherance of Zimmer,s pending acquisition of Biomet, ... Zimmer continues to work constructively with the Bureau of ...
(Date:5/28/2015)... -- Maetrics ( http://maetrics.com ), a leading international consulting firm ... successful conference, "The cost of non-compliance -- How new regulation ... Zurich . Hosted by ... Switzerland -based team, experts provided insights on the ... an exclusive local audience. The event was held in ...
(Date:5/28/2015)... , May 28, 2015 The controversy ... )  in hysterectomies and myomectomies (procedures to remove uterine ... the FBI is investigating Johnson & Johnson,s Ethicon, ... of the devices. According to the report published ... th , the FBI is trying to determine ...
Breaking Medicine Technology:Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 2Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 3Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 4Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 5Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 6Maetrics Hosts Innovative Medical Cluster Event in Switzerland 2Power Morcellator Attorneys at Bernstein Liebhard LLP Comment on Report That FBI Is Investigating Ethicon Morcellators 2Power Morcellator Attorneys at Bernstein Liebhard LLP Comment on Report That FBI Is Investigating Ethicon Morcellators 3
... Inc., a private clinical-stage biotherapeutics company focused on the ... for cancer, today announced that the first patient has ... JX-594 as a neoadjuvant therapy in patients who are ... to the liver. The study is ...
... 21, 2011  Adeona Pharmaceuticals, Inc. (NYSE Amex: ... of Directors has taken several actions to prioritize the ... field of synthetic biology. As previously announced on November ... into a worldwide exclusive channel collaboration for the development ...
Cached Medicine Technology:Jennerex Announces First Patient Treated in Phase 2a Clinical Trial of JX-594 as a Neoadjuvant Therapy in Colorectal Cancer Patients Undergoing Surgery 2Jennerex Announces First Patient Treated in Phase 2a Clinical Trial of JX-594 as a Neoadjuvant Therapy in Colorectal Cancer Patients Undergoing Surgery 3Jennerex Announces First Patient Treated in Phase 2a Clinical Trial of JX-594 as a Neoadjuvant Therapy in Colorectal Cancer Patients Undergoing Surgery 4Jennerex Announces First Patient Treated in Phase 2a Clinical Trial of JX-594 as a Neoadjuvant Therapy in Colorectal Cancer Patients Undergoing Surgery 5Adeona Announces Proposed Name Change to Synthetic Biologics, Inc., and Appointment of John Monahan, Ph.D., as Senior Vice President of Research & Development 2Adeona Announces Proposed Name Change to Synthetic Biologics, Inc., and Appointment of John Monahan, Ph.D., as Senior Vice President of Research & Development 3Adeona Announces Proposed Name Change to Synthetic Biologics, Inc., and Appointment of John Monahan, Ph.D., as Senior Vice President of Research & Development 4
(Date:5/28/2015)... Florida (PRWEB) May 28, 2015 Boston ... and wife Beth, both Genesis Foundation Board of Directors ... John Havlicek Celebrity Fishing Tournament June 4-7. For the ... 4-day event benefitting The Genesis Foundation for children by ... cause. , The 34th John Havlicek Celebrity Fishing ...
(Date:5/28/2015)... May 28, 2015 " Trends Investing ” ... Report, which takes a look at small, medium, and large ... host of NewsWatch and business expert, conducted the business review ... users to where they should invest their money. , The ... concept. But doing it and knowing how to succeed ...
(Date:5/28/2015)... Workers’ compensation costs per claim in Michigan ... study by the Workers Compensation Research Institute (WCRI) ... , The WCRI study, CompScope™ Benchmarks for Michigan, 15th ... days or more of work with those of 16 other ... claim was 4 percent lower than similar claims from 2008. ...
(Date:5/28/2015)... Nidra Herbal Sleep Supplement features a 100% Ayurveda herbal ... supplement, Nidra Herbal Sleep Supplement is more than just a ... with a real sense of wellbeing the next day. ... as the “Science or Knowledge of Life”, was first used ... holistic system of knowledge which combines contemplation, herbal supplements and ...
(Date:5/28/2015)... Ticket Down is a reputable source of presale tickets ... Argentina in early September. , Two of the best ... pitch at AT&T Stadium in Arlington/Dallas, TX. Mexico and Argentina ... Tuesday, September 8th at 9 p.m. The match will feature ... some of the most loved players in the entire sport. ...
Breaking Medicine News(10 mins):Health News:The Genesis Foundation Prepares for Their Final Annual John Havlicek Celebrity Fishing Tournament 2Health News:An Application to Learn Where to Invest Money was Featured on NewsWatch Television 2Health News:Michigan Workers’ Compensation Costs Lower Than Most States, Says WCRI Study 2Health News:Ayurveda Herba Corp’s Revolutionary Herbal Sleep Supplement is Now Available from Amazon.com 2Health News:Mexico vs. Argentina Tickets at AT&T Stadium: Ticket Down Slashes Ticket Prices on Argentina vs. Mexico Presale Tickets at AT&T Stadium for 9/8/15 Friendly Match 2Health News:Mexico vs. Argentina Tickets at AT&T Stadium: Ticket Down Slashes Ticket Prices on Argentina vs. Mexico Presale Tickets at AT&T Stadium for 9/8/15 Friendly Match 3
... office visits with a diagnosis of bipolar disorder substantially ... a bipolar disorder diagnoses appeared to almost double, according ... of General Psychiatry, one of the JAMA/Archives journals. , ... periods of mania (an abnormally elevated mood) and depression. ...
... "Psoriasis Cure,Now," a nonprofit patient advocacy group, today released ... their kids head back to,school. The organization offers a ... off the internet and deliver to their child,s school,teacher; ... leading pediatric,dermatologist discussing how to treat psoriasis in children ...
... September 3 KFH has announced that it,has ... 13485 and ISO,9001:2000 quality management systems with the ... Sally Sennitt, MD, says: "We are delighted,to have ... working with BSI. It is a major milestone ...
... WASHINGTON, Sept. 2 New data about the ... news for thousands of,patients with cardiovascular disease, according ... These new findings,also underscore the crucial importance of ... implantation technique, and in prescribing a,strict regimen of ...
... -- Chinas efforts to control population growth in the ... in the future. , This prediction comes from a ... a year in China studying its geriatric policies and ... of internal medicine in the division of geriatric medicine ...
... Sept. 2 Oil Refineries Ltd. (TASE: ORL),(the "Company" ... has received a claim (the "Claim"), filed with the ... IDF units, against the Company,and nine other defendants. The ... plaintiffs allege they contracted due to their being in,the ...
Cached Medicine News:Health News:Study documents rapid increase in youth bipolar disorder diagnoses 2Health News:Psoriasis Cure Now offers 'Back to School' Resources for Parents of Children with Psoriasis 2Health News:Latest DES Analysis Stresses Importance of Physicians Well-Trained in Implantation Technique and Patient Follow-Up 2Health News:Latest DES Analysis Stresses Importance of Physicians Well-Trained in Implantation Technique and Patient Follow-Up 3Health News:China's 1-child policy could backfire on its elderly 2Health News:China's 1-child policy could backfire on its elderly 3Health News:Claim Filed Against the Company and Nine Other Defendants in the Haifa Magistrates Court 2
... has been selling replacement bulbs ... and we are extremely proud ... Check out our catalog of ... discount light bulbs specials. ...
... Bulb Direct has been selling ... since 1996, and we are ... satisfaction guarantee. Check out our ... see our discount light bulbs ...
... Bulb Direct has been selling ... since 1996, and we are ... satisfaction guarantee. Check out our ... see our discount light bulbs ...
... Direct has been selling replacement ... 1996, and we are extremely ... guarantee. Check out our catalog ... our discount light bulbs specials. ...
Medicine Products: